Abstract
This year’s ICAAC meeting was dominated by exciting late-stage development antibiotics that represent breakthroughs in covering pathogens of unmet medical need, including drug-resistant pathogens. There are several exciting antibiotics in late-stage development, among them, linezolid, gatifloxacin, moxifloxacin, SB-265805, HMR 3647, SCH27899 and the resurrected daptomycin. The development of new technology for screening and the cross-application into genomics have led to numerous breakthroughs in techniques and strategies for the identification of novel prokaryotic targets.